232 related articles for article (PubMed ID: 32898249)
1. PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
Serrat N; Guerrero-Hernández M; Matas-Céspedes A; Yahiaoui A; Valero JG; Nadeu F; Clot G; Di Re M; Corbera-Bellalta M; Magnano L; Rivas-Delgado A; Enjuanes A; Beà S; Cid MC; Campo E; Montero J; Hodson DJ; López-Guillermo A; Colomer D; Tannheimer S; Pérez-Galán P
Blood Adv; 2020 Sep; 4(17):4217-4231. PubMed ID: 32898249
[TBL] [Abstract][Full Text] [Related]
2. The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.
Watanabe T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069564
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.
Bodo J; Zhao X; Durkin L; Souers AJ; Phillips DC; Smith MR; Hsi ED
Oncotarget; 2016 Oct; 7(43):70000-70010. PubMed ID: 27661108
[TBL] [Abstract][Full Text] [Related]
4. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
5. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Davids MS; Roberts AW; Kenkre VP; Wierda WG; Kumar A; Kipps TJ; Boyer M; Salem AH; Pesko JC; Arzt JA; Mantas M; Kim SY; Seymour JF
Clin Cancer Res; 2021 Sep; 27(17):4690-4695. PubMed ID: 34083230
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Elias EE; Sarapura Martinez VJ; Amondarain M; Colado A; Cordini G; Bezares RF; Fernandez Grecco H; Custidiano MDR; Sánchez Ávalos JC; Garate G; Pavlovsky MA; Borge M; Giordano M; Gamberale R
Cancer Immunol Immunother; 2022 Apr; 71(4):979-987. PubMed ID: 34467417
[TBL] [Abstract][Full Text] [Related]
7. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
Matas-Céspedes A; Rodriguez V; Kalko SG; Vidal-Crespo A; Rosich L; Casserras T; Balsas P; Villamor N; Giné E; Campo E; Roué G; López-Guillermo A; Colomer D; Pérez-Galán P
Clin Cancer Res; 2014 Jul; 20(13):3458-71. PubMed ID: 24799524
[TBL] [Abstract][Full Text] [Related]
8. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment.
Rawal S; Chu F; Zhang M; Park HJ; Nattamai D; Kannan S; Sharma R; Delgado D; Chou T; Lin HY; Baladandayuthapani V; Luong A; Vega F; Fowler N; Dong C; Davis RE; Neelapu SS
J Immunol; 2013 Jun; 190(12):6681-93. PubMed ID: 23686488
[TBL] [Abstract][Full Text] [Related]
9. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Isidori A; Loscocco F; Visani G; Paolasini S; Scalzulli P; Musto P; Perrone T; Guarini A; Pastore D; Mazza P; Tonialini L; Pavone V; De Santis G; Tarantini G
Br J Haematol; 2022 Nov; 199(3):339-343. PubMed ID: 36002151
[TBL] [Abstract][Full Text] [Related]
10. Development of venetoclax for therapy of lymphoid malignancies.
Zhu H; Almasan A
Drug Des Devel Ther; 2017; 11():685-694. PubMed ID: 28331288
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells.
Ludwig LM; Hawley KM; Banks DB; Thomas-Toth AT; Blazar BR; McNerney ME; Leverson JD; LaBelle JL
Cell Death Dis; 2021 Oct; 12(11):1005. PubMed ID: 34707089
[TBL] [Abstract][Full Text] [Related]
13. High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma.
Li Z; Pan G; Zhong M; Zhang L; Yu X; Zha J; Xu B
Int J Toxicol; 2023; 42(5):386-406. PubMed ID: 37271574
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
Thus YJ; De Rooij MFM; Swier N; Beijersbergen RL; Guikema JEJ; Kersten MJ; Eldering E; Pals ST; Kater AP; Spaargaren M
Haematologica; 2023 Mar; 108(3):797-810. PubMed ID: 36226498
[TBL] [Abstract][Full Text] [Related]
15. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):18-9. PubMed ID: 25768998
[No Abstract] [Full Text] [Related]
17. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
de Weerdt I; Hofland T; de Boer R; Dobber JA; Dubois J; van Nieuwenhuize D; Mobasher M; de Boer F; Hoogendoorn M; Velders GA; van der Klift M; Remmerswaal EBM; Bemelman FJ; Niemann CU; Kersting S; Levin MD; Eldering E; Tonino SH; Kater AP
Blood Adv; 2019 Sep; 3(17):2642-2652. PubMed ID: 31506282
[TBL] [Abstract][Full Text] [Related]
18. Differential Expression of Bcl-2 Family Proteins Determines the Sensitivity of Human Follicular Lymphoma Cells to Dexamethasone-mediated and Anti-BCR-mediated Apoptosis.
Adem J; Ropponen A; Eeva J; Eray M; Nuutinen U; Pelkonen J
J Immunother; 2016 Jan; 39(1):8-14. PubMed ID: 26641257
[TBL] [Abstract][Full Text] [Related]
19. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
